System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Argyris Tzouvelekis is an expert in Pulmonology at University of Patras (Greece). As of July 2026, ScienceLeadR ranks Argyris Tzouvelekis in the top 1% of experts worldwide for Lung Diseases, Interstitial. Argyris Tzouvelekis has authored 335 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 5 of them ongoing. SLR score: 1,118 (community average: 125). How the SLR is computed.

LeadR Profile

Argyris Tzouvelekis University of Patras Greece
1 118 ScienceLeadR Reputation 1118

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Immunology - Public Health - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

I am Professor of Internal and Respiratory Medicine at the University of Patras, Greece and Head of the Department of Respiratory Medicine at the University Hospital of Patras, Greece as well as Associate Professor Adjunct at Pulmonary Critical Care and Sleep Medicine Department, Yale School of Medicine, USA. From 2019 – 2022 I was also an Executive Officer-Internal Auditor of European Respiratory Society and since 2018 i serve as a member of the European Respiratory Society (ERS) College of Experts, official reviewer of ERS fellowships and Awards, mentor of ERS young scientists (ERS mentoring scheme), Associate Editor of Respiratory Research and Frontiers in Medicine. I am the head of the ERS Task Force on IPF and Lung cancer. I enumerate 282 publications in Scopus and 270 in PubMed with 8729 citations and H-index 50 ( 31% as first author, 23% as last author, and 46% as middle author).




Organizations

Career arc: 2004 - 2026
Source: PubMed

General University Hospital of Patras

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 335

Citations

Citations: 8 603 1st author: 73 Last author: 84 Unique author: 1

Main journals

Respiration 24
Front Med (Lausanne) 22
12.01 - Idiopathic interstitial pneumonias 19
Am J Respir Crit Care Med 16
Lancet Respir Med 11

Best Journals

N Engl J Med 4
Lancet Respir Med 3
Eur Respir J 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling.
PMID 42196858 — lung, fibrosis, biomarkers, pulmonary fibrosis, fibroblasts, therapeutics, tissues, adipokines, adipose tissue		Diagnostics (Basel)20260
Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment of acute exacerbations of idiopathic pulmonary fibrosis.
PMID 42164489 — idiopathic pulmonary fibrosis, mortality, fibrosis, hospital mortality, immunoglobulins, pulmonary fibrosis, therapeutics, immunoglobulins, intravenous		Front Immunol20260
A statistical Model for Lung Function Trajectory and Mortality in Patients with Fibrotic Interstitial Lung Disease.
PMID 42085272 — bias, mortality, lung, critical care, therapeutics, lung diseases, vital capacity, models, statistical, lung diseases, interstitial		Am J Respir Crit Care Med20260
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.
PMID 42085224 — idiopathic pulmonary fibrosis, fibrosis, critical care, pulmonary fibrosis, therapeutics, vital capacity		Am J Respir Crit Care Med20260
Pleural fluid neutrophil extracellular traps are associated with disease severity and risk of one-year mortality in pleural infection. An observational, international, multicohort study (TORPIDS-3).
PMID 42025308 — mortality, respiration, neutrophils, therapeutics, extracellular traps, infections		Eur Respir J20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 4
Phase 2 3
N/A 2
Phase 2/Phase 3 1

By status:

Completed 4
Active not recruiting 3
Recruiting 3

By type:

Interventional 8
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT07299695 — quinolones, idiopathic pulmonary fibrosis, hospitalization, methylprednisolone, fibrosis, adrenal cortex hormones, premedication, heparin, immunoglobulins, acetaminophen, pulmonary fibrosis, therapeutics, heparin, low-molecular-weight, pulse, immunoglobulins, intravenous, fondaparinux		Phase 3Recruiting2026
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis
NCT06588686 — idiopathic pulmonary fibrosis, angiotensin ii, safety, fibrosis, angiotensins, pulmonary fibrosis, therapeutics		Phase 2Active not recruiting2024
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
NCT05926505 — safety, syringes, signs and symptoms, covid-19, immune system, receptors, interleukin-1, interleukin-1, interleukin 1 receptor antagonist protein, therapeutics, post-acute covid-19 syndrome		Phase 2/Phase 3Recruiting2023
Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy
NCT05681962 — lung, blood, fibrosis, bronchoalveolar lavage, neoplasms, blood pressure, bronchoscopy, biopsy, respiratory insufficiency, cell biology, lung neoplasms, pulmonary fibrosis, pneumonia, endoscopy, records, lung diseases, ventilation, outpatients, cannula, lung diseases, interstitial, cytology		N/ARecruiting2023
LYT 100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420 — respiration disorders, idiopathic pulmonary fibrosis, lung, safety, fibrosis, respiration, pulmonary fibrosis		Phase 2Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS